Monoclonal Gammopathy of Undetermined Significance (MGUS)
Symptoms, Doctors, Treatments, Advances & More

Monoclonal Gammopathy of Undetermined Significance (MGUS) Overview

Save information for later
Sign Up

Learn About Monoclonal Gammopathy of Undetermined Significance (MGUS)

What is the definition of Monoclonal Gammopathy of Undetermined Significance (MGUS)?
Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop.
What are the alternative names for Monoclonal Gammopathy of Undetermined Significance (MGUS)?
  • Monoclonal gammopathy of undetermined significance
  • MGUS
Who are the top Monoclonal Gammopathy of Undetermined Significance (MGUS) Local Doctors?
Elite in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Prashant Kapoor
Hematology | Oncology
Elite in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Prashant Kapoor
Hematology | Oncology
Referral may be required

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
507-910-0296
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Prashant Kapoor is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Kapoor is rated as an Elite provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Waldenstrom Macroglobulinemia, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant. Dr. Kapoor is currently accepting new patients.

Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Suzanne Lentzsch
Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Suzanne Lentzsch
Hematology | Oncology
Referral may be required

CUIMC/Herbert Irving Pavilion

161 Fort Washington Avenue, 
New York, NY 
212-305-5098
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzanne Lentzsch is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Lentzsch is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy. Dr. Lentzsch is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Robert A. Bayer
Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Robert A. Bayer
Hematology | Oncology
Referral may be required
10 Health Service Dr, 
Dekalb, IL 
815-756-5255
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Bayer is a Hematologist and an Oncologist practicing medicine in Dekalb, Illinois. Dr. Bayer is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). He is also highly rated in 53 other conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Lynch Syndrome, Colorectal Cancer, and Pancreatic Cancer. Dr. Bayer is currently accepting new patients.

View All Doctors
What are the latest Monoclonal Gammopathy of Undetermined Significance (MGUS) Clinical Trials?
Specified Use-Results Study of ILARIS Solution for S.C. Injection (Schnitzler's Syndrome)
Specified Use-Results Study of ILARIS Solution for S.C. Injection (Schnitzler's Syndrome)
Enrollment Status: Recruiting
Publish Date: September 03, 2026

Summary: The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Zanubrutinib, a Second Generation BTK Inhibitor, in Anti-MAG Antibody Neuropathy: a Phase II Italian Multicenter Clinical Trial (MAZINGA)
Zanubrutinib, a Second Generation BTK Inhibitor, in Anti-MAG Antibody Neuropathy: a Phase II Italian Multicenter Clinical Trial (MAZINGA)
Enrollment Status: Recruiting
Publish Date: August 28, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The MAZINGA study is a multicenter, open-label, single-arm Phase IIA clinical trial designed to evaluate the efficacy, safety, and tolerability of zanubrutinib in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) antibody-associated demyelinating polyneuropathy. Anti-MAG neuropathy is a rare immune-mediated disorder frequently associated with IgM monoclonal gammopathies, including m...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center